Merck & Co (NY:MRK)

120.28 +0.45 (+0.38%)

Official Closing Price Updated: 4:10 PM EST, Mar 4, 2026 Add to My Watchlist

Price and Volume

Volume	6,702,775
Open	119.43
Bid (Size)	119.00 (100)
Ask (Size)	121.20 (200)
Prev. Close	119.83
Today's Range	117.86 - 120.87
52wk Range	73.31 - 125.14
Shares Outstanding	2,531,374,696
Dividend Yield	2.83%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth

Today 14:15 EST

In a classic case of "selling the news," shares of ImmunityBio, Inc. (NASDAQ: IBRX) took a sharp dive on Wednesday, March 4, 2026, plummeting over 13% to close at $9.02. The sell-off came as a surprise...

Via MarketMinute

2 High-Flying Stocks With More Upside to Buy and Hold ↗

Today 9:32 EST

It's not too late to get in on the action.

Via The Motley Fool

Performance

YTD	+13.0%	+13.0%
1 Month	+6.1%	+6.1%
3 Month	+19.1%	+19.1%
6 Month	+40.7%	+40.7%
1 Year	+29.1%	+29.1%

More News

IBRX Stock Tumbles After-Hours: Flags ‘Terrible’ BCG Shortage As Saudi Anktiva Launch Nears Amid Middle East Tensions ↗

March 03, 2026

Via Stocktwits

IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗

March 03, 2026

Via Stocktwits

USDA Deploys $100 Million 'Screwworm Challenge' to Safeguard U.S. Livestock and Dairy Frontier

March 02, 2026

Via MarketMinute

IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend ↗

March 02, 2026

Via Stocktwits

KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)

February 28, 2026

From Merck & Co., Inc

Via Business Wire

WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

February 28, 2026

From Merck & Co., Inc.

Via Business Wire

3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade ↗

February 28, 2026

Via The Motley Fool

Big Tech’s Heavy Lifting: S&P 500 Q4 Earnings Surpass 8% Growth Amid AI Capex Anxiety

February 27, 2026

Via MarketMinute

What's going on in today's session: S&P500 movers ↗

February 27, 2026

Via Chartmill

Industrial Renaissance: Sector Surges 27% in Q4 2025 as Healthcare and Consumer Discretionary Lag

February 27, 2026

Via MarketMinute

KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer

February 27, 2026

From Merck & Co., Inc.

Via Business Wire

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

February 27, 2026

From Merck & Co., Inc.

Via Business Wire

Merck's Two-Drug HIV Regimen Challenges Industry Standards Following Positive Phase 3 Results

February 26, 2026

Via MarketMinute

Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy

February 26, 2026

Via MarketMinute

The Moonshot Medicine: United Therapeutics Surges on Record Earnings and TreSMI Breakthrough

February 26, 2026

Via Finterra

United Therapeutics (UTHR) Deep Dive: Strong Q4 and the ‘Inhalation Evolution’

February 26, 2026

Via Finterra

Gilead’s Twice-Yearly HIV Breakthrough: A Paradigm Shift in Global Prevention and Market Dominance

February 25, 2026

Via MarketMinute

Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics

February 25, 2026

Via MarketMinute

FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis

February 25, 2026

From Merck & Co., Inc.

Via Business Wire

Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026

February 25, 2026

From Merck & Co., Inc.

Via Business Wire

Merck to Participate in the TD Cowen 46th Annual Health Care Conference

February 24, 2026

From Merck & Co., Inc.

Via Business Wire

Merck Evolves Human Health Operating Structure to Support Portfolio Execution

February 23, 2026

From Merck & Co., Inc.

Via Business Wire

Merck Is Reportedly Splitting Its Pharma Division As Keytruda Patent Nears 2028 Expiry ↗

February 23, 2026

Via Stocktwits

Frequently Asked Questions

Is Merck & Co publicly traded?

Yes, Merck & Co is publicly traded.

What exchange does Merck & Co trade on?

Merck & Co trades on the New York Stock Exchange

What is the ticker symbol for Merck & Co?

The ticker symbol for Merck & Co is MRK on the New York Stock Exchange

What is the current price of Merck & Co?

The current price of Merck & Co is 120.28

When was Merck & Co last traded?

The last trade of Merck & Co was at 03/04/26 04:10 PM ET

What is the market capitalization of Merck & Co?

The market capitalization of Merck & Co is 304.47B

How many shares of Merck & Co are outstanding?

Merck & Co has 304B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.